Guiseppe Saglio

28PUBLICATIONS
151CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsBiologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Jul 22, 2026
Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network.

|May 22, 2026
From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia.

|Jan 19, 2026
Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.

Delphine Rea, Slawomira Kyrcz-Krzemien, Paolo Sportoletti

|Jan 11, 2026
Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort study.

Massimo Breccia, Valentina Giai, Tiziana Rosso

|Nov 18, 2025
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.

Fausto Castagnetti, Massimo Breccia, Elisabetta Abruzzese

|Aug 08, 2025
Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE Study.

Alessandra Iurlo, Massimo Breccia, Fabio Stagno

Pageof 5

Frequent Collaborators

8 joint publications

Massimo Breccia

6 joint publications

Paola Circosta

5 joint publications

Massimiliano Bonifacio

4 joint publications

Marta Giorgis